Registry for patients with chronic thromboembolic disease
Official title: Chronic Thromboembolic Disease: A Prospective Registry
Run by University of California, San Francisco · NCT05843500 · Data updated 2026-11-12
This study is collecting information from patients with chronic thromboembolic disease to see how different treatments affect their health and quality of life over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | July 1, 2028 |
| Study ends | July 1, 2028 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT05843500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with chronic thromboembolic disease or chronic thromboembolic pulmonary hypertension.
✕Probably not a fit
Patients with pulmonary hypertension from causes other than chronic thromboembolic disease may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry aims to gather data on the natural history of patients diagnosed with chronic thromboembolic disease (CTD) and chronic thromboembolic pulmonary hypertension (CTEPH). It will assess long-term outcomes following various treatments, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy. Participants will be followed over time to evaluate their health outcomes and quality of life through chart reviews and health quality surveys.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into treatment effectiveness and improve management strategies for patients with chronic thromboembolic disease.
How similar studies have gone: Other studies have shown success in understanding chronic thromboembolic disease through registries, indicating that this approach is both valuable and tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred with CTED and/or CTEPH defined as: 1. Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH) 2. Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram 3. Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension * Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH * Age ≥ 18 years Exclusion Criteria: * Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH) * Patient's refusal to participate in clinical research and/or receive intervention
Where it's running
-
University of California San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Miles Conrad, MD — University of California, San Francisco
- Study coordinator: Miles Conrad, MD
- Email: miles.conrad@ucsf.edu
- Phone: (415) 353-1300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up
This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.
-
Nailfold Capillaroscopy in Pulmonary Hypertension
This study tests whether nailfold capillary scans correlate with invasive lung blood pressure measurements and whether these patterns change with PH treatment.
-
How pulmonary endarterectomy affects confidence in managing chronic thromboembolic pulmonary hypertension
This project will see if pulmonary endarterectomy helps people with chronic thromboembolic pulmonary hypertension feel more confident managing their condition.
-
Registry of people with chronic thromboembolic pulmonary hypertension in Russia
This registry collects health, history, and treatment information from people in Russia with chronic thromboembolic pulmonary hypertension to see which factors relate to their prognosis.
-
Effects of stopping riociguat on heart function in patients with CTEPH
This study is testing how stopping the medication riociguat affects heart function in patients with inoperable CTEPH who have had balloon pulmonary angioplasty.
-
Switching from Sildenafil to Riociguat for CTEPH Patients
This study is testing if switching from sildenafil to riociguat can help people with Chronic Thromboembolic Pulmonary Hypertension feel better after they’ve already had balloon pulmonary angioplasty.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.